Impax Laboratories Inc. is in talks to combine with rival Amneal Pharmaceuticals LLC as the companies seek to build strength in a challenging market for generic-drug makers. Impax and closely held Amneal are in talks that could yield a transaction next month, assuming they don’t fall apart, according to people familiar with the matter. Terms couldn’t be learned, but Impax had a market value of about $1.6 billion Thursday morning...

Source: Wall Street Journal September 21, 2017 16:30 UTC